TY - JOUR AU - Guba, Andrea AU - Takácsi-Nagy, Anna AU - Das, Sourav AU - Szokol, Bálint AU - Medveczki, Tímea AU - Vajna, Márton Antal AU - Kalló, Gergő AU - Fekete, Andrea AU - Hodrea, Judit AU - Csősz, Éva TI - UHPLC-MS-Based Analysis of Fluvoxamine in Rabbit Aqueous Humour and Serum: Method Development and Validation JF - PHARMACEUTICALS J2 - PHARMACEUTICALS-BASE VL - 19 PY - 2026 IS - 2 PG - 13 SN - 1424-8247 DO - 10.3390/ph19020260 UR - https://m2.mtmt.hu/api/publication/36919961 ID - 36919961 N1 - * Megosztott szerzőség AB - Background/Objectives: Fluvoxamine (FLU) is a selective serotonin reuptake inhibitor and one of the most potent agonists of the sigma-1 receptor. Emerging evidence shows that FLU exerts protective effects in multiple organs, making it a promising candidate for topical ocular therapy. Developing an FLU eyedrop for glaucoma can address a significant treatment gap with potentially fewer side effects compared with conventional therapies. To optimise formulation development, precise quantification of FLU in ocular compartments such as aqueous humour, as well as systemic circulation, is essential to characterise drug absorption, ocular bioavailability, and safety. Methods: We developed and validated a UHPLC-MS method for FLU detection in aqueous humour and serum using simple sample preparation steps. Results: The 11-min-long reverse phase chromatography followed by SRM-based mass spectrometry detection provides a highly selective and sensitive FLU detection method. Our method was proved to be linear in the 0.0625–1.5 µg/mL range and was validated according to the EMA guidelines. Conclusions: The simplicity of sample preparation, the tolerable matrix effects, and the favourable detection parameters provide a robust tool for preclinical pharmacokinetic and pharmacodynamic studies of FLU’s ocular protective effects. LA - English DB - MTMT ER - TY - CONF AU - Medveczki, Tímea AU - Hodrea, Judit AU - Tran, Ngoc Minh AU - Takácsi-Nagy, Anna AU - Lakat, Tamás AU - Szokol, Bálint AU - Kovács, Illés AU - Török, György AU - Fekete, Andrea TI - Új hatásmechanizmusú anti-glaukómás szemcsepp preklinikai fejlesztése T2 - Selye EKÖP Tudományos Fórum 2025 PY - 2025 SP - 26 EP - 27 PG - 2 UR - https://m2.mtmt.hu/api/publication/36094044 ID - 36094044 N1 - OTKA- K135398, LP2021-3/2021, TKP2021-EGA-24, STAGE 2024-1.2.3-HU-RIZONT-2024-00056. A Kulturális és Innovációs Minisztérium 2024-2.1.1-EKÖP-2024-0004 kódszámú egyetemi kutatói ösztöndíj programjának a nemzeti kutatási, fejlesztési és innovációs alapból finanszírozott szakmai támogatásával készült. LA - Hungarian DB - MTMT ER - TY - GEN AU - Medveczki, Tímea AU - Hodrea, Judit AU - Tran, Ngoc Minh AU - Anna, Takacsi-Nagy AU - Tóth, Ákos Roland AU - Lakat, Tamás AU - Őrfi, László AU - Szokol, Bálint AU - Kovács, Illés AU - Eva, Csosz AU - Gyorgy, Torok AU - Szabó, Attila AU - Fekete, Andrea TI - Fluvoxamine, a Sigma-1 receptor agonist, is a new and innovative therapy for glaucoma PY - 2025 UR - https://m2.mtmt.hu/api/publication/36094470 ID - 36094470 N1 - {előadás} LA - English DB - MTMT ER - TY - CONF AU - Hodrea, Judit AU - Medveczki, Tímea AU - Lakat, Tamás AU - Tran, Ngoc Minh AU - Tóth, Ákos Roland AU - Takacsi-Nagy, A AU - Szokol, Bálint AU - Török, György AU - Szabó, Attila AU - Kovács, Illés AU - Prokai, L AU - Fekete, Andrea TI - A newly developed fluvoxamine eyedrop for glaucoma treatment T2 - 5th European Symposium,1st Meeting of SIGMA-1 EUROPE - Physiopathology of Sigma-1 Receptors PY - 2025 SP - 46 EP - 46 PG - 1 UR - https://m2.mtmt.hu/api/publication/36226133 ID - 36226133 LA - English DB - MTMT ER - TY - CONF AU - Medveczki, Tímea AU - Hodrea, Judit AU - Tran, Ngoc Minh AU - Takacsi-Nagy, A AU - Lakat, Tamás AU - Tóth, Ákos Roland AU - Szokol, Bálint AU - Kovács, Illés AU - Török, György AU - Szabó, Attila AU - Fekete, Andrea TI - Age-specific anti-glaucomatous effect of a Fluvoxamine-containing eye drop T2 - 5th European Symposium,1st Meeting of SIGMA-1 EUROPE - Physiopathology of Sigma-1 Receptors PY - 2025 SP - 94 EP - 94 PG - 1 UR - https://m2.mtmt.hu/api/publication/36226170 ID - 36226170 LA - English DB - MTMT ER - TY - CONF AU - Tóth, Ákos Roland AU - Lakat, Tamás AU - Budai, András AU - Szokol, Bálint AU - Őrfi, László AU - Szabó, Attila AU - Fekete, Andrea AU - Hosszú, Ádám TI - Protective effects of a novel Sigma-1 receptor agonist in renal ischemia/reperfusion injury T2 - 5th European Symposium,1st Meeting of SIGMA-1 EUROPE - Physiopathology of Sigma-1 Receptors PY - 2025 SP - 98 EP - 98 PG - 1 UR - https://m2.mtmt.hu/api/publication/36226195 ID - 36226195 LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Ákos Roland AU - Lakat, Tamás AU - Budai, András AU - Szokol, Bálint AU - Őrfi, László AU - Kerkó, Marcell AU - Wagner, J. László AU - Szabó, Attila AU - Fekete, Andrea AU - Hosszú, Ádám TI - Új Sigma-1 receptor agonista kezelés protektív hatású a renális iszkémia/reperfúzós károsodással szemben JF - HYPERTONIA ÉS NEPHROLOGIA J2 - HYPERTONIA NEPHROLOGIA VL - 29 PY - 2025 IS - Suppl. 5 SP - 47 EP - 48 PG - 2 SN - 1418-477X UR - https://m2.mtmt.hu/api/publication/36370245 ID - 36370245 N1 - Támogatás: LP2021-3/2021, TKP2021-EGA-24, STAGE 2024-1.2.3-HU-RIZONT-2024-00056 LA - Hungarian DB - MTMT ER - TY - PAT AU - KOVÁCS, KRISZTIÁN ANDRÁS AU - KALESNYKAS, GIEDRIUS AU - Szokol, Bálint AU - ILLYÉS, ESZTER] AU - SZABADKAI, ISTVÁN TI - IN VIVO TARGETING OF THERAPEUTIC MOLECULES TO THE RETINA VIA THE OPTICAL SYSTEM OF THE EYE PY - 2025 UR - https://m2.mtmt.hu/api/publication/36384948 ID - 36384948 LA - English DB - MTMT ER - TY - PAT AU - Krisztián, András KOVÁCS AU - Giedrius, KALESNYKAS AU - Szokol, Bálint AU - Eszter, ILLYÉS AU - István, SZABADKAI TI - NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES PY - 2025 UR - https://m2.mtmt.hu/api/publication/36435731 ID - 36435731 LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Ákos Roland AU - Lakat, Tamás AU - Budai, András AU - Kállay, Hanga AU - Szokol, Bálint AU - Wágner, László József AU - Őrfi, László AU - Kreko, Marcell AU - Szabó, Attila AU - Fekete, Andrea AU - Hosszú, Ádám TI - Novel Sigma-1 receptor agonist alleviates renal ischemic injury by targeting apoptotic and inflammatory pathways JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 15 PY - 2025 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-025-23459-0 UR - https://m2.mtmt.hu/api/publication/36437689 ID - 36437689 AB - Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury, yet its mechanisms remain unclear, and effective treatments are lacking. We previously showed that the Sigma-1 receptor (S1R) agonist fluvoxamine protects against IRI and IRI-induced graft injury during transplantation. Here, we developed a novel compound, 'VCC904125', with potent S1R affinity and minimal blood-brain barrier penetration to mitigate renal IRI without psychoactive side effects. Mice were treated with VCC904125 before clamping the left renal pedicles, followed by contralateral nephrectomy. VCC904125 markedly alleviated BUN and serum creatinine levels, KIM-1 and NGAL expression, and structural damage at both 24 and 48 h after reperfusion. S1R activation by VCC904125 targets key pathways underlying IRI, including apoptosis and inflammation. VCC904125 treatment impeded the apoptotic p53-Bax pathway and influenced CaMKII-NF-κB signaling, resulting in diminished proinflammatory cytokine expression. In the ex vivo model, kidneys were perfused and stored in an HTK preservation solution supplemented with VCC904125 to simulate cold storage conditions before transplantation. VCC904125 ameliorated structural injury profoundly after cold ischemia. Taken together, S1R activation by VCC904125 decreases renal IRI via ameliorating apoptotic and inflammatory pathways. These results highlight the therapeutic promise of S1R activation in mitigating cold and warm ischemia and improving transplant outcomes. LA - English DB - MTMT ER -